Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2023 –2030 | |
|
|
USD 1,765.80 million |
| USD 2,908.17 million | |
| % | |
|
Global Apixaban Market, By Dosage Form (Capsule and Tablets), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.
The market is projected to observe major growth during the forecast period. Apixaban is generally indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market in both capsule and tablet form. The development of advanced anticoagulants increases the demand and provides numerous options to patients and healthcare professionals.
Data Bridge Market Research analyses a growth rate in the global apixaban market in the forecast period 2023-2030. The expected CAGR of the global apixaban market tends to be around 5.70% in the mentioned forecast period. The market was valued at USD 1,765.8 million in 2022 and would grow to USD 2,908.17 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Dosage Form (Capsule and Tablets), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan NV (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GSK plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Lilly (US), Amgen Inc. (US), Eisai Co., Ltd (Japan), Aspen Holdings (South Africa), Fresenius Kabi AG (Germany), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), OPOCRIN SPA (Italy), SARIA International GmbH (Germany), Hepalink Group (China)., Shenzhen Techdow Pharmaceutical Co., Ltd (China), Yino Pharma Limited (China)
|
|
Market Opportunities
|
|
Market Definition
Apixaban is an FDA-approved anticoagulant which is used for the treatment of venous thromboembolic events that forms inside a vein. Venous thromboembolic events (VTE) can occur without any typical symptoms or warning signs. The common symptoms associated with either deep vein thrombosis (DVT) or either pulmonary embolism (PE) are chest pain, pain in the calf, redness or noticeable discoloration spots, swelling in the ankle or foot, and others.
Drivers
The growing prevalence of venous thromboembolism-related conditions is anticipated to help grow the market. According to American Heart Association, VTE affects around 300,000 to 600,000 Americans yearly. The records of the International Society on Thrombosis and Haemostasis 2014 revealed that about 10 million cases of venous thromboembolism occur yearly across low, middle, and high-income countries. Thus, it acts as a major driver in market growth.
The development of various advanced anticoagulants increases the demand and provides numerous options to patients and healthcare professionals. Apixaban has undergone large clinical trials and received FDA approval for several indications. Apixaban is a significant anticoagulant that acts by blocking certain clotting proteins in the blood.
Opportunities
There has been an increasing development in the research end front, creating many opportunities for market growth. For instance, the ARISTOTLE trial showed that apixaban is superior to warfarin in decreasing stroke and systemic embolism in patients with atrial fibrillation. Pfizer collaborated with Bristol-Myers Squibb to develop and commercialize apixaban; the alliance strengthens both companies to expand potential in cardiovascular drug development and commercialization.
The apixaban is the third non-vitamin K antagonist oral anticoagulant used for clinical practice. The regular dose of apixaban is highly effective in decreasing thromboembolic events compared to warfarin. In December 2019, the US FDA approved the first generics of apixaban tablets, and FDA's generic drug program enables access to cost-effective and high-quality drugs
Restraints/Challenges
Several adverse effects of apixaban, such as the increased risk of thrombotic events after premature discontinuation and bleeding, are projected to hamper this drug's usage. This, in turn, is estimated to adversely affect the market's growth.
To treat conditions that are rare, several times, all treatments are not available, particularly in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.
This global apixaban market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global apixaban market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The COVID-19 pandemic significantly impacted the global apixaban market. COVID-19 patients often develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm, and complement cascade hyperactivation. Numerous medications are being used for the treatment of COVID-19 patients. Sarilumab and tocilizumab can increase cytochrome P450 enzyme activity, so they should not be used together with apixaban or rivaroxaban and may also increase the doses of warfarin required. The thrombotic risk is linked with disease severity and worsens patients' prognosis; the management strategies need to be assessed.
The global apixaban market is segmented on the basis of dosage form, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Dosage Form
End-Users
Distribution Channel
The global apixaban market is analysed and market size insights and trends are provided by dosage form,end-user, distribution channel as referenced above.
The major countries covered in the global apixaban market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the highest investment in healthcare and awareness.
Asia-Pacific is considered to have the most lucrative period because of the developing healthcare facilities, large number of generic manufacturers, and increase in government initiatives
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The global apixaban market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global apixaban market.
Key players operating in the global apixaban market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.